METHODS: We report a pathologically proven clinical case of primary central nervous system vasculitis in a 50-year-old man with a diagnosis of relapsing-remitting multiple sclerosis after alemtuzumab therapy, which required additional immunosuppression to control this life-threatening condition.
CONCLUSIONS: In patients presenting subacute neurological deterioration after alemtuzumab therapy, primary central nervous system vasculitis should be considered as a differential diagnosis among other autoimmune conditions.
方法:我们报告了一例50岁男性经病理证实的原发性中枢神经系统血管炎的临床病例,在阿仑珠单抗治疗后诊断为复发缓解型多发性硬化,这需要额外的免疫抑制来控制这种危及生命的状况。
结论:阿仑珠单抗治疗后出现亚急性神经恶化的患者,原发性中枢神经系统血管炎应作为其他自身免疫性疾病的鉴别诊断。